OncoMatch/Clinical Trials/NCT06017583
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
Is NCT06017583 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Tislelizumab and Capecitabine for rectal neoplasms.
Treatment: Tislelizumab · Capecitabine · Oxaliplatin — This study aims to evaluate the efficacy and safety of tislelizumab combined with simultaneous integrated boost intensity-modulated radiotherapy in treating locally advanced rectal cancer. To explore a new PD-1 inhibitor adjuvant chemotherapy model combined with radiotherapy to treat locally advanced rectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-PD-1 therapy
The subject has previously received other PD-1 or PD-L1, or CTLA-4 antibody therapy, or other drug therapy targeting immunoregulatory receptor preparations.
Cannot have received: anti-PD-L1 therapy
The subject has previously received other PD-1 or PD-L1, or CTLA-4 antibody therapy, or other drug therapy targeting immunoregulatory receptor preparations.
Cannot have received: anti-CTLA-4 therapy
The subject has previously received other PD-1 or PD-L1, or CTLA-4 antibody therapy, or other drug therapy targeting immunoregulatory receptor preparations.
Lab requirements
Blood counts
HB≥90g/L, ANC≥1.5×10^9/L, PLT≥80×10^9/L
Kidney function
plasma Cr≤1.5 ULN or creatinine clearance ≥60 ml/min
Liver function
TBIL≤1.5 ULN, ALT and AST≤2.5 ULN
blood routine: HB≥90g/L, ANC≥1.5×10^9/L, PLT≥80×10^9/L; Biochemical examination of ALB≥30g/L, TBIL≤1.5 ULN, ALT and AST≤2.5 ULN, plasma Cr≤1.5 ULN or creatinine clearance ≥60 ml/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06017583 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, anti-PD-L1 therapy, anti-CTLA-4 therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify